REQUIRED CLINICAL DOCUMENTATION FOR REVIEW

Documentation required to determine medical necessity for Ibandronate (Boniva): History and/or physical examination notes and relevant specialty consultation notes that address the problem and need for the service: -Diagnosis -Labs/diagnostics - Medication list (current and past) to include start and end dates of previous trials for all bisphosphonate therapies -Initial/extended approval -Dosing and duration of therapy.

BACKGROUND

Boniva injection is a bisphosphonate that inhibits osteoclast-mediated bone resorption. Boniva injection is indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women with osteoporosis, Boniva injection increases bone mineral density (BMD) and reduces the incidence of vertebral fractures.1 The recommended dose for the treatment of postmenopausal osteoporosis is 3 mg every 3 months administered intravenously (IV) over a period of 15 to 30 seconds.

DEFINITIONS

None.

INDICATIONS/Criteria

<table>
<thead>
<tr>
<th>Medicaid Members</th>
<th>Continue to criteria for approval below.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicare Members</td>
<td>Step-utilization of Part D drugs not required.</td>
</tr>
</tbody>
</table>

Coverage of Boniva injection is recommended in those who meet one of the following criteria:

FDA-Approved Indications

1. Osteoporosis Treatment for a Postmenopausal Patient.

Criteria. *Patient must meet the following criteria (A AND B).*

A) The patient meets ONE of the following conditions (i, ii, or iii):
i. The patient has had a T-score (current or at any time in the past) at or below -2.5 at the lumbar spine, femoral neck, total hip, and/or 33% (one-third) radius (wrist); OR

ii. The patient has had an osteoporotic fracture or a fragility fracture; OR

iii. The patient has low bone mass (T-score [current or at any time in the past] between -1.0 and -2.5 at the lumbar spine, femoral neck, total hip, and/or 33% [one-third] radius [wrist]) and the physician determines that the patient is at high risk for fracture; AND

B) The patient meets ONE of the following (i, ii, iii, or iv):

i. The patient has tried one oral bisphosphonate or oral bisphosphonate-containing product and meets one of the following (1, b, or c):
   a) The patient has had an inadequate response to oral bisphosphonate therapy after a trial duration of 12 months as determined by the prescribing physician (e.g., ongoing and significant loss of BMD, lack of BMD increase); OR
   b) The patient has had an osteoporotic fracture or a fragility fracture while receiving oral bisphosphonate therapy; OR
   c) The patient has experienced intolerability to an oral bisphosphonate (e.g., severe gastrointestinal (GI)-related adverse effects); OR

ii. The patient cannot take an oral bisphosphonate due to one of the following circumstances: (a, b, or c):
   a) The patient cannot swallow or has difficulty swallowing; OR
   b) The patient cannot remain in an upright position post oral bisphosphonate administration; OR
   c) The patient has a pre-existing GI medical condition in which IV bisphosphonate therapy may be warranted (e.g., patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]); OR

iii. The patient has tried ibandronate injection (Boniva IV) or zoledronic acid injection (Reclast); OR

iv. The patient has had an osteoporotic fracture or a fragility fracture.

Boniva injection is indicated for the treatment of osteoporosis in postmenopausal women. Many oral bisphosphonate products are indicated and have proven efficacy. In 2016 the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology updated clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis. Approved agents with efficacy to reduce hip, non-vertebral and spine fractures include alendronate, risedronate, Reclast® (zoledronic acid injection), and Prolia® (denosumab injection for subcutaneous use) which are appropriate as initial therapy for most patients at high-risk of fracture. Forteo® (teriparatide injection for subcutaneous use), Prolia or Reclast should be considered for patients unable to use oral therapy and as initial therapy for patients who are at especially high-risk of fracture. Evista® (raloxifene tablets) or ibandronate may be appropriate initial therapies in some scenarios in which patients require medications with spine-specific efficacy. Concomitant use of agents for the prevention or treatment of postmenopausal osteoporosis is not recommended. In the AACE guidelines for PMO, osteoporosis is defined as a T-score of -2.5 or below in the lumbar spine, femoral neck or total hip and/or 33% (one-third radius) or as the presence of fragility fractures in the absence of other metabolic bone disorders. IV bisphosphonate therapy may be preferred in some instances over oral therapy (e.g., GI intolerance, a
pre-existing GI medical condition). Oral bisphosphonates are contraindicated if patients have abnormalities of the esophagus which delay emptying (stricture or achalasia). Patients must also not lie down for at least 30 minutes post-oral bisphosphonate administration. In the professional opinion of specialist physicians reviewing the data, we have adopted these criteria.

**Dosing in the Treatment of Osteoporosis in a Postmenopausal Patient.** Dosing must meet the following: The dose is 3 mg IV every 3 months.

**Initial Approval/Extended Approval.**

A) *Initial Approval.* Initial approval is for 12 months.

B) *Extended Approval.* Approve at 12-month intervals.

**Duration of Therapy in the Treatment of Osteoporosis in a Postmenopausal Patient.** Therapy is indefinite.

**Labs/Diagnostics.** Monitor renal function before each dose. The patient must have a calculated creatinine clearance (CrCl) ≥ 30 mL/min. In those without osteoporotic fractures, patients must have had a T-score (current or at any time in the past) at or below -2.5, or low bone mass (T-score [current or at any time in the past] between -1.0 and -2.5) the physician determines that the patient is at high risk of fracture. If the CrCl is not given, an example of how to calculate CrCl is provided in Appendix A (see page 4).

**Waste Management for All Indications:**

Boniva injection is available as one prefilled syringe in a strength of 3 mg/3 mL. This dose should be sufficient in most situations.

**Conditions Not Recommended for Approval**

Boniva injection has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions.

1. **Osteoporosis Prevention.** Ibandronate injection (Boniva IV) is not indicated for the prevention of osteoporosis and supporting data are limited.

2. **Concurrent Use of ibandronate injection (Boniva IV) with Other Medications for Osteoporosis** (e.g., other bisphosphonates [previously listed], Prolia® [denosumab injection for subcutaneous use], Forteo® [teriparatide for subcutaneous (SC) use], Tymlos® [abaloparatide injection for SC use], calcitonin nasal spray), except calcium and Vitamin D.

3. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

**SPECIAL CONSIDERATIONS**

None.
LIMITATIONS/EXCLUSIONS

Please refer to a product line’s certificate of coverage for benefit limitations and exclusions for these services:

<table>
<thead>
<tr>
<th>PRODUCT LINE</th>
<th>LINK TO CERTIFICATE OF COVERAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>WASHINGTON APPLE HEALTH</td>
<td><a href="http://chpw.org/our-plans/apple-health/">http://chpw.org/our-plans/apple-health/</a></td>
</tr>
<tr>
<td>INTEGRATED MANAGED CARE</td>
<td><a href="http://chpw.org/our-plans/apple-health/">http://chpw.org/our-plans/apple-health/</a></td>
</tr>
</tbody>
</table>

Citations & References

References

2. Boniva® tablets [prescribing information]. South San Francisco, CA: Genentech USA/Roche; December 2016.

CFR

WAC 284-43-2050

RCW

Contract Citation

☐ WAH
☐ IMC
☐ MA

Other Requirements

DATA CONTAINED IN THIS DOCUMENT IS CONSIDERED CONFIDENTIAL AND PROPRIETARY INFORMATION AND ITS DUPLICATION USE OR DISCLOSURE IS PROHIBITED WITHOUT PRIOR APPROVAL OF COMMUNITY HEALTH PLAN OF WASHINGTON.
<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Revision Description</th>
<th>Revision Made By</th>
</tr>
</thead>
<tbody>
<tr>
<td>01/13/2016</td>
<td>New</td>
<td>Kelly Force; Yusuf Rashid, RPh</td>
</tr>
<tr>
<td>01/20/2016</td>
<td>Approval</td>
<td>MMLT</td>
</tr>
<tr>
<td>01/12/2017</td>
<td>No revisions</td>
<td>Fran McGaugh</td>
</tr>
<tr>
<td>01/13/2017</td>
<td>Approval</td>
<td>MMLT</td>
</tr>
<tr>
<td>07/24/2017</td>
<td>Criteria completely updated and revised</td>
<td>Michael Sporck, Pharmacy Intern Sophia Yun, PharmD</td>
</tr>
<tr>
<td>07/25/2017</td>
<td>Approved</td>
<td>MMLT</td>
</tr>
<tr>
<td>03/09/2018</td>
<td>Reassigned from UM153 to PM138</td>
<td>Cindy Bush</td>
</tr>
<tr>
<td>05/07/2018</td>
<td>Transferred to new template</td>
<td>Cindy Bush</td>
</tr>
<tr>
<td>06/12/2018</td>
<td>Revised</td>
<td>Jennifer Farley, PharmD</td>
</tr>
<tr>
<td>06/14/2018</td>
<td>Approval</td>
<td>UM Committee</td>
</tr>
</tbody>
</table>
Appendix A: Cockcroft-Gault Equation for Estimating Creatinine Clearance

There are many different methods that can be used to calculate an estimated creatinine clearance (CrCl). The Cockcroft-Gault is one formula that provides an estimate of CrCl using serum creatinine. It is only for adults. This formula tends to overestimate CrCl in obese persons and to underestimate it in those who are lean. The Cockcroft-Gault equation for calculating CrCl is as follows:

CrCl in adults \( \text{(men)} \) = \( \frac{140 \text{ minus age [in years]} \times \text{weight [in kg]}}{72 \times \text{serum creatinine [in mg/dL]}} \)

For women, multiply the above results by 0.85. The steps, for clarity, are as follows:

1) Subtract the patient’s age in years from 140.
2) Multiply by the patient’s weight in kg (if weight is in pounds, divide by 2.2 to get kg).
3) Multiply the patient’s serum creatinine (in mg/dL) by 72.
4) Divide the total from 2) by the total from 3).
5) If the patient is female, take the total from 4) and multiple by 0.85.

For example, a man who is 55 years of age, who weighs 160 pounds (72.7 kg), and with a serum creatinine 0.9 mg/dL, would have a calculated creatinine clearance of 95 mL/minute. For a woman with these same values, her CrCl would be 81 mL/minute.